共 123 条
[1]
Jay D(2006)Oxidative stress and diabetic cardiovascular complications Free Radic Biol Med 40 183-192
[2]
Hitomi H(2015)Diabetes mellitus: the epidemic of the century World J Diabetes 6 850-867
[3]
Griendling KK(2017)A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data J Diabetes Complicat 31 1719-1727
[4]
Kharroubi AT(2016)Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus–mechanisms, management, and clinical considerations Circulation 133 2459-2502
[5]
Darwish HM(2014)Prevention and management of type 2 diabetes: dietary components and nutritional strategies Lancet 383 1999-2007
[6]
Gourgari E(2011)Patient adherence to medication requirements for therapy of type 2 diabetes Int J Clin Pract 65 314-322
[7]
Wilhelm EE(2014)The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat J Pharmacol Exp Ther 350 657-664
[8]
Hassanzadeh H(2015)Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med 373 2117-2128
[9]
Aroda VR(2017)Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial Lancet Diabetes Endocrinol 5 610-621
[10]
Shoulson I(2016)SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia 59 1333-1339